Regenerative Biologics Supplier for Orthopedic Practices in Scranton, PA

Vendor qualification for orthopedic practices

Orthopedic practices and ambulatory surgery centers typically run a short vendor qualification process before adding a new biologics supplier: confirming the supplier's registration and licensure documentation is available for review, requesting a certificate of analysis and donor eligibility summary for a representative lot, and checking that account access is tied to a verifiable NPI number rather than an open storefront.

Precision Biologics structures account setup around that process. Access to ordering requires NPI verification, and documentation such as the lot release record and donor eligibility summary is provided to verified accounts on request rather than published generally.

Receiving and cold-chain handling

Cryopreserved Wharton's jelly and exosome formats ship overnight on dry ice in validated containers and are stored at -80 degrees C on arrival; lyophilized formats are shelf-stable and handled per the insert included with each lot. A practice in Scranton receiving shipments should plan for a staff member to be available to move cryopreserved product into storage promptly after delivery, and to log the lot identifier against the patient record for traceability.

Confirming regulatory posture before ordering

Each product is offered under the supplier's own documentation framework, and whether a specific intended use at the practice qualifies under 21 CFR 1271.10 is a determination for the practice and its own counsel, not something Precision Biologics advises on. Practices in Pennsylvania evaluating a new biologics line typically confirm their own standing with the Pennsylvania State Board of Medicine and consult counsel before finalizing a purchasing decision, since Precision Biologics does not provide clinical, dosing, or protocol guidance.

Setting up a verified account

Account setup starts with NPI verification and a short review of the practice's licensure documentation. Once an account is verified, ordering access, verified-account pricing, and physician-level calls about product documentation become available; those calls address documentation and specifications, not clinical decisions.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.